newsfilter
← Earnings
Earnings Releases·

Rapid Micro Biosystems — Third Quarter 2026 Earnings Summary

  • Financial Performance:

    • Total revenue increased 21.6% year-over-year to $9.5 million for the quarter ended September 30, 2026, compared to $7.8 million in the same period in 2025.
    • Product revenue rose 24.9% to $6.5 million, while service revenue increased 14.9% to $3.0 million.
    • Recurring revenue grew 6.9% to $5.2 million.
    • Total gross margin reached a record 25.2% ($2.4 million), an increase of 16.3 percentage points from 8.9% in the third quarter of 2025.
    • Product gross margin increased 19 percentage points to 12%, and service gross margin increased 14 percentage points to 54% compared to the prior year quarter.
    • Total operating expenses increased 8.1% to $13.0 million, including a non-recurring restructuring charge of $0.7 million.
    • Net loss was $11.3 million ($0.23 per share), compared to a net loss of $11.5 million ($0.26 per share) in the third quarter of 2025.
    • Non-GAAP adjusted EBITDA loss improved to $7.9 million from $9.4 million in the prior year quarter.
    • Cash, cash equivalents, and short-term investments totaled approximately $7 million as of September 30, 2026.
    • Deferred revenue was $4.4 million as of September 30, 2026, down from $4.7 million as of December 31, 2025.
    • Notes payable, net, stood at $19.2 million as of September 30, 2026.
  • Guidance and Future Outlook:

    • The Company withdrew its full year 2026 guidance following the announcement of the acquisition agreement.
    • The Company will not host a conference call to discuss the financial results.
    • The filing of the Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, is delayed to allow for additional financial reporting and disclosure matters related to the acquisition.
  • Business Segments and Product Lines:

    • The Company placed seven new Growth Direct systems and completed validations for 12 customer systems in the third quarter of 2026, compared to five placements and four validations in the third quarter of 2025.
    • The Growth Direct platform automates and modernizes microbial quality control testing workflows for pharmaceutical manufacturing operations.
  • Market and Competitive Landscape:

    • The Company highlighted a strong partnership with Merck KGaA, Darmstadt, Germany, focused on innovation and modernizing quality control workflows.
    • The Growth Direct platform is utilized in the largest and most complex pharmaceutical manufacturing operations globally.
  • Risks and Challenges:

    • The press release outlines forward-looking risks including the possibility that closing conditions for the proposed acquisition may not be satisfied.
    • Risks include uncertainty regarding the percentage of stockholders supporting the acquisition, potential stockholder litigation, and the risk that the acquisition may not be completed in the expected timeframe or at all.
    • Potential adverse effects during the pendency of the acquisition include employee departures and management distraction.
    • Other risks include the Company's ability to achieve positive cash flow, its history of significant losses, and the ability to meet business objectives.
  • Management Commentary and Tone:

    • Rob Spignesi, President and CEO, expressed pleasure with 22% total revenue growth driven by both Product and Service businesses.
    • Management noted continued progress in gross margin expansion initiatives, resulting in record Product and Service gross margins.
    • The CEO expressed pride in the team's accomplishments and the global impact of the Growth Direct platform.
    • Management stated confidence that joining Merck KGaA will significantly expand the Growth Direct platform's reach and accelerate adoption.
  • Other Key Points:

    • The Company signed a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany.
    • The acquisition is subject to terms and conditions set forth in the agreement.
    • A tender offer statement on Schedule TO and a solicitation/recommendation statement on Schedule 14D-9 will be filed with the SEC when the tender offer commences.
    • The Company intends to use its Investor Relations website to disclose material nonpublic information and comply with Regulation FD.
Company
RAPID MICRO BIOSYSTEMS INC
Sector
Healthcare
Industry
Medical Devices